Pipeline of Combination Therapies | Incannex

featured Programs

Obstructive Sleep Apnea |IHL-42X

IHL-42X is an oral fixed-dose combination therapy of acetazolamide and dronabinol currently in clinical studies for the treatment of obstructive sleep apnea (OSA).

swipe
IHL-42X

Obstructive Sleep Apnea
- RePOSA
  
  Ph 2/3 Safety & Efficacy Trial
  
  560-patient, randomized, double-blind safety and efficacy study
  
  Dosing started May 2024
- BA/BE
  
  Bioavailability Trial
  
  115-subject, bioavailability and bioequivalence study
  
  Dosing completed July 2024
- POC
  
  Ph 2 Trial
  
  Crossover, safety and efficacy study
  
  Study completed
Rheumatoid Arthritis |IHL-675A

IHL-675A is an oral fixed-dose combination of a synthetic cannabidiol and hydroxychloroquine sulfate (HCQ) that is currently in Phase 2 development for the treatment of rheumatoid arthritis (RA).

swipe
IHL-675A

Rheumatoid Arthritis
- Phase 2
  
  Ph 2 Safety and Efficacy Study
  
  128-patient, double-blind, safety and efficacy study
  
  Dosing started January 2024
- Phase 1
  
  Ph 1 Safety and PK Study
  
  36-patient, Phase 1 safety and PK study
  
  Study completed
Generalized Anxiety Disorder |PSX-001

PSX-001 is an oral synthetic psilocybin currently being studied in combination with psychological support as a treatment for adults with generalized anxiety disorder (GAD).

swipe
PSX-001

Generalized Anxiety Disorder
- PsiGAD2
  
  Ph 2 Dose Comparison
  
  94-patient, double-blind, safety and efficacy study
- PsiGAD1
  
  Ph 2 Trial
  
  73-patient, double-blind, safety and efficacy study
  
  Dosing completed January 2024

Patients

joyful female smiling with hands on chest

joyful female smiling with hands on chest

Patients

We are working urgently to develop innovative therapies for patients with obstructive sleep apnea (OSA), rheumatoid arthritis (RA), and generalized anxiety disorder (GAD).

Get in touch to learn more about our programs and to receive updates.